Perrigo (PRGO)
Health Care · Consumer healthcare and specialty pharmaceuticals · NYSE
A struggling diversified consumer and prescription healthcare manufacturer navigating portfolio restructuring and strategic divestitures amid margin pressure and competitive headwinds.
What Perrigo does
Perrigo is a global healthcare company that develops, manufactures, and distributes over-the-counter consumer healthcare products, prescription medications, and nutritional products across multiple markets. The company operates through consumer self-care and prescription business segments, serving retail customers and consumers worldwide. Perrigo is currently undergoing a strategic review involving proposed divestitures of its Dermacosmetics branded business and other business units to reshape its portfolio.
Themes: Consumer self-care / OTC healthcare, Prescription pharmaceuticals, Nutritional supplements, Dermatology / cosmetics, Rare diseases
Fundamentals
- Price$14.25 as of 2026-08-21 close
- Market cap$2.0B as of 2026-08-21
- 1-year return-39.2% 2025-08-21 close $23.43 → 2026-08-21 close $14.25
- P/En/a negative earnings
- Net margin-41.9% as of 2026-08-24
- Gross margin+33.3% as of 2026-08-24
- ROE-56.0% as of 2026-08-24
- Debt / equity1.31 as of 2026-08-24
- Revenue growth (YoY)-4.2% as of 2026-08-24
- Revenue CAGR (3y)-1.5% SEC XBRL
- Beta0.68 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +3.5%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How PRGO compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldtop 25% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, PRGO's dividend exceeded at least one reported measure of what it earned or generated (free-cash-flow payout 110%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payoutnot assessable earnings were not positive that year
- Free-cash-flow payout110% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Perrigo looks technically
Perrigo (PRGO) is trading 15.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 250 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70). It just made a new 20-day high, its first since 2026-02-25, pushing above its recent trading range. It is 42.1% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 15.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +15.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.10 | $11.10 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $12.36 | $12.36 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 12.1699. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 250 trading days ago — a "death cross", a bearish long-term signal | 250 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 15.3% above | +15.3% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control | 36.9 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70) | 71.5 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($10.36 to $14.26) — its "stochastic" reading is 100 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 99.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $24.61 | $24.61 |
|---|---|---|
| From the 52-week high | it is 42.1% below its 52-week high (its highest price of the past year) | -42.1% |
| Above the 52-week low | it is 54.5% above its 52-week low (its lowest price of the past year) | +54.5% |
| Below the 52-week high | it is 42.1% below its highest point of the past year | 42.1% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-02-25, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2026-02-25, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $215.73 (set on 2015-04-08) | $215.73 |
| Given back of the 52-week move | over the past year its closes ranged ($9.25 to $24.49), and it has recovered roughly a third of its fall from last year’s high — 33% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $18.67 to $19.16. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 32.8% |
| From the all-time high | it is 93.4% below its all-time high | -93.4% |
| Nearest price level | it is trading 4.4% above a support level at $13.62 — a price it turned at twice since 2026-01-29, most recently on 2026-08-05. Since 2024-08-21 it has 7 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.4% |
| All-time low | its lowest closing price on record is $9.22 (set on 2026-03-20) | $9.22 |
| Above the all-time low | it is 54.5% above its all-time low | +54.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 87% of the past ~6 months) | 87th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6195 between its high and its low — about 4.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6195 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $9.42 and $14.89 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $9.42 – $12.16 – $14.89 |
| Typical daily range (% of price) | its price moves about 4.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.3% |
| Stretch from the 200-day average | it is trading 3.1 daily ranges above its 200-day average price (15.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.93× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a hammer | 7 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 7 sessions ago |
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.1% |
|---|---|---|
| Open gap | it gapped 17.1% above the previous close 12 sessions ago and has not traded back through the level it left behind at 10.78 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +17.1% |
| Gap filled | a 2.1% gap down opened on 2026-08-12 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 6 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 33.8 percentage points (the stock gained 36.1% while the market gained 2.3%) | +33.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 22.5 percentage points (the stock gained 25.6% while the market gained 3.1%) | +22.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 15.9 percentage points (the stock lost 4.8% while the market gained 11.1%) | -15.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 59.7 percentage points (the stock lost 39.2% while the market gained 20.5%) | -59.7% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, its RSI momentum gauge is overbought (a stretched reading), lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 30% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.1% of the share price. | +29.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 22% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $11.69 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +21.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $13.12 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +8.6% |
Price levels it has turned at before
PRGO last closed at $14.25 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $13.62 | Support | 4.4% below the last close | turned there twice · 2026-01-29 to 2026-08-05 |
| $12.66 | Support | 11.2% below the last close | turned there twice · 2025-12-16 to 2026-05-06 |
| $12.16 | Support | 14.7% below the last close | turned there three times · 2025-11-21 to 2026-08-12 |
| $20.64 | Resistance | 44.8% above the last close | turned there twice · 2025-09-22 to 2025-10-10 |
| $23.87 | Resistance | 67.5% above the last close | turned there four times · 2024-10-10 to 2025-04-10 |
| $24.61 | Resistance | 72.7% above the last close | turned there twice · 2025-05-06 to 2025-08-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $12.17.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $13.13 and $14.68 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 2 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Pulled back from the 12-month high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.40 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$16.50 range $14.00 – $20.00; median $16.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PRGO
- Consensus EPS estimate$0.5319 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Inability to complete proposed divestitures of Dermacosmetics business and other units, including receipt of required regulatory and works council approvals and counterparty performance on deferred payments","Severe pricing pressures from customers and consumers, combined with intensifying competition from larger competitors with greater marketing resources and market share in key product categories","Supply chain disruptions and geopolitical risks from armed conflicts (Ukraine, Middle East), trade sanctions, and tariffs that impact manufacturing and operations; product recall risks and regulatory approval uncertainties"]
What changed in the latest 10-Q
AI-assisted comparison of PRGO's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K for year ended December 31, 2025 (newer filing) vs. December 31, 2024 (older filing)
- Reference to Item 1A of 2025 Form 10-K (newer) vs. 2024 Form 10-K (older)
- Quotation marks around 'Perrigo' in corporate description in newer filing
- New reporting segment structure: Self Care, Specialty Care, Infant Formula, and All Other (replacing CSCA and CSCI segments)
- New products table detailing product categories across reporting segments
- Products organized by Self Care (Upper Respiratory, Digestive Health, Healthy Lifestyle, Pain and Sleep-Aids), Specialty Care (Skin Health, Women's Health), Infant Formula, and All Other (Oral Care, Other)
- Reference to Opill ® and Mederma ® as brands in North America section
- Note that Dermacosmetics business is now included within Other category (previously in Skin Care)
- Phrase 'healthy lifestyle and women's health' replaces 'nutrition and women's health' in North America description
- Removed:
- Reference to Supply Chain Reinvention Program and Project Energize initiatives (previously detailed)
- Detailed explanation of complementary businesses with mention of 'store brands and infant formula' and 'High-Grow' brands
- Statement about 'leveraging global supply chain scale with 100-plus molecules, at 100% consumer price point coverage'
- Detailed 'Three-S' plan description specifying stabilizing 'Consumer Self-Care Americas store brand and infant formula businesses,' streamlining 'global portfolio, enterprise operating model and Consumer Self-Care International business,' and strengthening 'High-Grow' brands
- Operating segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI)
- Recent Developments section (including KKR Dermacosmetics Business sale and infant formula strategic review announcements)
- Reference to Note 5 (changed to Note 4 in newer filing)
- Reworded:
- Strategic goal description changed from listing four numbered items to simplified language about 'sustainable and value accretive growth' with numbered items reordered
- 'Three-S' plan simplified from specific business references to general 'Stabilizing,' 'Streamlining,' and 'Strengthening' language without detailed context
- North America product categories: 'nutrition' removed and 'healthy lifestyle' added as category descriptor
- Complementary business explanation condensed significantly, removing detailed cash generation and investment mechanics
- Supply chain scale description changed from 'global supply chain scale and reach with 100-plus molecules, at 100% consumer price point coverage' to 'global supply chain scale with more molecules at more price points to more consumers'
- Notes:
- Older filing text appears truncated at 'Restructuring Supply Chain Reinve' - comparison limited to complete text available
- Segment structure fundamentally changed from geographic (CSCA/CSCI) to product-category based (Self Care, Specialty Care, Infant Formula, All Other), suggesting material reorganization
- Recent Developments section entirely removed from newer filing, though this may reflect timing of the 10-Q periods rather than deletion of information
Risk Factors
- Added:
- Added reference to 'ongoing conflict and social, political and economic environment in Israel and the broader Middle East' (filed 2026-05-06)
- Added phrase 'and strategic review processes described herein' to restructuring and strategic initiatives language (filed 2026-05-06)
- Updated 10-K reference year from 'December 31, 2024' to 'December 31, 2025' (filed 2026-05-06)
- Reworded:
- Changed 'the Middle East' to 'the ongoing conflict and social, political and economic environment in Israel and the broader Middle East' - expanded scope and specificity of geographic risk disclosure (filed 2026-05-06 vs 2025-11-05)
- Notes:
- The newer filing (2026-05-06) section appears truncated after the forward-looking statements and trademarks sections; full Risk Factors section text was not provided for comparison
- The older filing (2025-11-05) section also appears truncated; complete Risk Factors Item 1A content was not provided for detailed line-by-line comparison
- Comparison is limited to the Cautionary Note regarding Forward-Looking Statements section which appears in both filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for PRGO — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
PRGO had 23,148,167 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PRGO had 16.7% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.28 days to cover at the same settlement.
- Reported short interest (shares) 23,148,167
- Short interest (% of shares outstanding) 16.7%
- Prior settlement (shares) 22,934,211
- Reported change 0.93%
- Days to cover (reported) 8.28
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Church & Dwight (CHD)
- Prestige Consumer Healthcare (PBH)
- Procter & Gamble Health (PG)
- Reckitt Benckiser Group
- Chattem (part of Sanofi)
- Haleon
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PRGO vs…
Perrigo is found in…
Frequently asked questions
What does Perrigo (PRGO) do?
Perrigo is a global healthcare company that develops, manufactures, and distributes over-the-counter consumer healthcare products, prescription medications, and nutritional products across multiple markets. The company operates through consumer self-care and prescription business segments, serving retail customers and consumers worldwide.
What sector is Perrigo (PRGO) in?
Perrigo (PRGO) is classified in the Health Care sector. Its industry is Consumer healthcare and specialty pharmaceuticals. It trades on NYSE.
Does PRGO pay a dividend?
Yes — Perrigo (PRGO) pays a dividend, with an indicated yield of about 3.54% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Perrigo's (PRGO) competitors?
Notable peers of Perrigo (PRGO) include Church & Dwight, Prestige Consumer Healthcare, Procter & Gamble Health, Reckitt Benckiser Group and Chattem (part of Sanofi). This peer set is informational only — not financial advice.
Is Perrigo (PRGO) overbought or oversold right now?
Perrigo (PRGO) is currently in overbought territory (its 14-day RSI is 72, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PRGO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.